[Animal Modeling]-Ermidine in the pulmonary hypertension model

  Objective: To investigate the preventive and therapeutic effects of anitidine (DIZE) on pulmonary hypertension (PAH) model rats.

  Method: Left lobectomy combined with subcutaneous injection of monochromatic Tallinn (MCT) into the abdominal wall to establish a PAH rat model. From the blank control group (group A) and the DIZE control group, 100 adult male Wistar rats were randomly selected. (Group B), PAH model group (C group), DIZE treatment PAH model group (D group) and (DIZE + C-16) treatment PAH model group (E group), active fluorescence resonance energy transfer (FRET)) and enzymes -How to measure and calculate the level of angiotensin converting enzyme 2 (ACE2), serum IL-6 and IL-8, mean pulmonary artery pressure (mPAP), right ventricular hypertrophy index (RVHI) measured by Link immunosorbent assay (ELISA) The effect of ratio thickness on pulmonary artery outer diameter (WT), intimal hyperplasia score, and analysis of pulmonary vascular disease by elastic fiber staining.

  Results: Comparison of RVHI, ACE2 enzyme activity, WT and intimal hyperplasia scores: The difference between group C, D, and E was statistically significant compared with group A (P\u003c0.05), with statistically significant academic significance (P\ u003c0.05). The five groups have statistically significant differences in the overall analysis of each index (P\u003c0.05).

  Conclusion: Elmidin can increase the activity of ACE2 enzyme, effectively reduce mPAP, RVHI and WT, while reducing pulmonary arterioles media hypertrophy and inhibiting pulmonary arterioles intimal hyperplasia. The conclusions of this study provide an experimental basis for the treatment of human PAHs with Hermitin.